Pedro Mateu-Gelabert1, H Guarino2, K Quinn2,3, P Meylakhs4, S Campos2, A Meylakhs4, D Berbesi5, D Toro-Tobón6, E Goodbody2, D C Ompad7, S R Friedman2. 1. National Development Research Institutes, Inc., 71 West 23rd Street, 4th Floor, New York, NY, 10010, USA. mateu-gelabert@ndri.org. 2. National Development Research Institutes, Inc., 71 West 23rd Street, 4th Floor, New York, NY, 10010, USA. 3. Department of Population Health, New York University, New York City, NY, USA. 4. International Centre for Health Economics, Management and Policy, National Research University Higher School of Economics, St. Petersburg, Russia. 5. School of Nursing, CES University, Medellín, Colombia. 6. School of Medicine, CES University, Medellín, Colombia. 7. College of Global Public Health, New York University, New York City, NY, USA.
Abstract
PURPOSE OF REVIEW: The social networks of people who inject drugs (PWID) have long been studied to understand disease transmission dynamics and social influences on risky practices. We illustrate how PWID can be active agents promoting HIV, HCV, and overdose prevention. RECENT FINDINGS: We assessed drug users' connections and interactions with others at risk for HIV/HCV in three cities: New York City (NYC), USA (n = 539); Pereira, Colombia (n = 50); and St. Petersburg, Russia (n = 49). In all three cities, the majority of participants' network members were of a similar age as themselves, yet connections across age groups were also present. In NYC, knowing any opioid user(s) older than 29 was associated with testing HCV-positive. In NYC and St. Petersburg, a large proportion of PWID engaged in intravention activities to support safer injection and overdose prevention; in Pereira, PWID injected, had sex, and interacted with other key groups at risk. People who use drugs can be active players in HIV/HCV and overdose risk- reduction; their networks provide them with ample opportunities to disseminate harm reduction knowledge, strategies, and norms to others at risk. Local communities could augment prevention programming by empowering drug users to be allies in the fight against HIV and facilitating their pre-existing health-protective actions.
PURPOSE OF REVIEW: The social networks of people who inject drugs (PWID) have long been studied to understand disease transmission dynamics and social influences on risky practices. We illustrate how PWID can be active agents promoting HIV, HCV, and overdose prevention. RECENT FINDINGS: We assessed drug users' connections and interactions with others at risk for HIV/HCV in three cities: New York City (NYC), USA (n = 539); Pereira, Colombia (n = 50); and St. Petersburg, Russia (n = 49). In all three cities, the majority of participants' network members were of a similar age as themselves, yet connections across age groups were also present. In NYC, knowing any opioid user(s) older than 29 was associated with testing HCV-positive. In NYC and St. Petersburg, a large proportion of PWID engaged in intravention activities to support safer injection and overdose prevention; in Pereira, PWID injected, had sex, and interacted with other key groups at risk. People who use drugs can be active players in HIV/HCV and overdose risk- reduction; their networks provide them with ample opportunities to disseminate harm reduction knowledge, strategies, and norms to others at risk. Local communities could augment prevention programming by empowering drug users to be allies in the fight against HIV and facilitating their pre-existing health-protective actions.
Entities:
Keywords:
HIV/HCV prevention; Opioid use; People who inject drugs; Young drug users
Authors: S R Friedman; A Neaigus; B Jose; R Curtis; M Goldstein; G Ildefonso; R B Rothenberg; D C Des Jarlais Journal: Am J Public Health Date: 1997-08 Impact factor: 9.308
Authors: Karsten Lunze; Anita Raj; Debbie M Cheng; Emily K Quinn; Fatima I Lunze; Jane M Liebschutz; Carly Bridden; Alexander Y Walley; Elena Blokhina; Evgeny Krupitsky; Jeffrey H Samet Journal: J Int AIDS Soc Date: 2016-07-18 Impact factor: 5.396
Authors: Barbara Tempalski; Enrique R Pouget; Charles M Cleland; Joanne E Brady; Hannah L F Cooper; H Irene Hall; Amy Lansky; Brooke S West; Samuel R Friedman Journal: PLoS One Date: 2013-06-05 Impact factor: 3.240
Authors: Louisa Degenhardt; Amy Peacock; Samantha Colledge; Janni Leung; Jason Grebely; Peter Vickerman; Jack Stone; Evan B Cunningham; Adam Trickey; Kostyantyn Dumchev; Michael Lynskey; Paul Griffiths; Richard P Mattick; Matthew Hickman; Sarah Larney Journal: Lancet Glob Health Date: 2017-10-23 Impact factor: 26.763
Authors: Peter Meylakhs; Samuel R Friedman; Anastasia Meylakhs; Pedro Mateu-Gelabert; Danielle C Ompad; Alisa Alieva; Alexandra Dmitrieva Journal: AIDS Behav Date: 2019-12
Authors: Adam Viera; Jacob J van den Berg; Collette D Sosnowy; Nikita A Mehta; E Jennifer Edelman; Trace Kershaw; Philip A Chan Journal: AIDS Behav Date: 2022-03-18
Authors: Samuel R Friedman; Leslie D Williams; Honoria Guarino; Pedro Mateu-Gelabert; Noa Krawczyk; Leah Hamilton; Suzan M Walters; Jerel M Ezell; Maria Khan; Jorgelina Di Iorio; Lawrence H Yang; Valerie A Earnshaw Journal: J Community Psychol Date: 2021-06-11
Authors: Lakshmi Ganapathi; Allison M McFall; Aylur K Srikrishnan; Muniratnam S Kumar; Santhanam Anand; Gregory M Lucas; Shruti H Mehta; Sion K Harris; Sunil S Solomon Journal: J Int AIDS Soc Date: 2019-05 Impact factor: 5.396
Authors: Abdul Rasheed; Hamid Sharifi; Paul Wesson; Sayed Jalal Pashtoon; Fatemeh Tavakoli; Nima Ghalekhani; Ali Akbar Haghdoost; Alim Atarud; Mohammad Reza Banehsi; Naqibullah Hamdard; Said Iftekhar Sadaat; Willi McFarland; Ali Mirzazadeh Journal: PLoS One Date: 2022-01-28 Impact factor: 3.240